Myriad Wields Proprietary Database To Protect Testing Market
This article was originally published in The Gray Sheet
Myriad president Mark Capone made it clear that the company will use its proprietary database of genetic variants on the BRCA1 and BRCA2 genes to try and fend off cheaper competition after the BRACAnalysis test’s method patents are expired, or if they are overturned in court.
You may also be interested in...
While the genetics firm is not wavering in its legal effort to protect its BRCA gene testing dominance, it is diversifying in response to inevitable competition, with a focus on a multigene panel and companion diagnostics.
With the Oct. 15 launch of the BRCAvantage genetic test, Quest Diagnostics Inc. became the latest entrant into the now-competitive marketplace for BRCA diagnostic testing for the likelihood of inheriting breast or ovarian cancer.
Olaparib is off the shelf and into a Phase III trial against ovarian cancer in platinum-sensitive BRCA-positive patients, adding to the list of late-stage PARP inhibitors vying for first-in-class status.